Panitumumab to prevent the progression of eyeball elongation in adults with nearsightedness and macular degeneration

Intravitreal panitumumab for prevention of myopic axial elongation in highly myopic adult eyes with myopic macular degeneration

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN96896687

Enrollment

Registered

2023-03-03

Start date

2021-11-05

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult highly myopic patients with myopic macular degeneration Eye Diseases

Interventions

Any patient attending the Ufa Eye Research Institute and Hospital and fulfilling the inclusion criteria could be included in the study. The intervention will consist of intraocular injection of panitu

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 26.0 mm 3. Myopic macular degeneration of stage 4 (foveal patchy atrophy) 4. Best corrected visual acuity >1.0 logMAR (logarithm of the minimal angle of resolution) (20/200 Snellen equivalent)

Exclusion criteria

Exclusion criteria: Not meeting the inclusion criteria

Design outcomes

Primary

Measure	Time frame
Intraocular safety, defined by signs of intraocular inflammation, such as cells in the aqueous humour, increased Tyndall phenomenon, cells in the vitreous body, intraocular pressure, measured by slit lamp biomicroscopy of the anterior and posterior segment of the eye and applanation tonometry, at baseline and at every re-examination, i.e., at day 1 and 7 and at one and two months after each injection to search for signs of acute inflammation	—

Measure

Time frame

Intraocular safety, defined by signs of intraocular inflammation, such as cells in the aqueous humour, increased Tyndall phenomenon, cells in the vitreous body, intraocular pressure, measured by slit lamp biomicroscopy of the anterior and posterior segment of the eye and applanation tonometry, at baseline and at every re-examination, i.e., at day 1 and 7 and at one and two months after each injection to search for signs of acute inflammation

—

Secondary

Measure	Time frame
Axial length, measured by laser interferometric biometry at baseline, at every re-injection, and at the study end at 6 months	—

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026